Leadership

September Riharb is the Chief Marketing Officer at Jeune Aesthetics, Inc. Ms. Riharb is a senior executive with experience in public and private aesthetic companies. She was a key member of the Evolus management team where she helped lead the Company’s successful IPO and commercialization of the Company’s flagship neurotoxin product Jeuveau®. Ms. Riharb was the Sr. Director of Strategic Planning and later the VP of Development for Allergan. She was also one of the aesthetic market pioneers with McGhan Medical and INAMED. In addition to her aesthetic experience, Ms. Riharb launched first-wave disruptive technologies in minimally invasive surgery and medical robotics; she was instrumental in commercializing the first surgical robots and voice-activated operating rooms. Ms. Riharb holds a Bachelor of Arts from California State University, Fullerton.

Marc Forth is President and Chief Executive Officer at AEON Biopharma, Inc., a biopharmaceutical company focused on the use of botulinum toxins for the treatment of debilitating medical conditions. Prior to AEON Biopharma, Mr. Forth was the Senior Vice President of Allergan PLC and Division Head for the U.S. Neurosciences, Urology and Medical Dermatology Division. During his 16 year tenure at Allergan, Mr. Forth was responsible for all aspects of the commercialization of both current and future products within Neurosciences, Urology and Medical Dermatology, most notably BOTOX for all therapeutic uses. Prior to Allergan, Mr. Forth held various Sales and Marketing roles of increasing responsibility at TAP Pharmaceuticals Inc., a specialty company focused on Urology, Oncology, Gynecology and Gastroenterology. Mr. Forth received a B.S. in Business Administration from California State University, Fresno and a Graduate Marketing Certification from Southern Methodist University.

Nishant Saxena brings extensive experience in life sciences, capital markets, and finance to his role as CFO at Jeune. Prior to joining Jeune, Mr. Saxena was a Managing Director in the strategic advisory practice focused on the biopharmaceutical sector at Evercore. In his over 15 years at Evercore, Mr. Saxena led numerous client engagements and advised on mergers and acquisitions, private placements, initial public offerings, follow-on offerings, partnerships, structured financings, and other transactions. Earlier in his career, Mr. Saxena held positions of increasing responsibility in private equity, venture capital, and investment advisory firms. Mr. Saxena received a B.S. in Economics and an MBA from the Wharton School at the University of Pennsylvania.

Krish Krishnan is the Chairman and CEO at Krystal Biotech. He is an accomplished biotech executive. He was specifically involved in two successful IPOs (COO/CFO of New River Pharmaceuticals, Inc., NASDAQ: NRPH) and COO of Intrexon Corporation, Inc., NYSE:XON), approval of the blockbuster drug Vyvanse (for ADHD in 2007) and the sale of New River Pharmaceuticals, Inc. to Shire Pharmaceuticals, plc for $2.6 billion. He served as the CEO of Pinnacle Pharmaceuticals, Inc. and advanced a potential treatment for urinary tract infection from discovery to Phase II. He has served as Board member for Biotie Therapies Oyi (BTH1V:Helsinki, NASDAQ: BITI), a specialized drug development company in Finland and Thar Pharmaceuticals,Inc. prior to its sale to Grunenthal GmbH in 2017. Previously, Krish served as a Managing Principal of Suppliermarket.com (a pharmaceutical B2B marketplace) that was sold to Ariba in 2001 for $500m. Krish started his career as a Senior Engineer at E.I.Dupont de Nemours. Krish has an undergraduate degree from the Indian Institute of Technology and a graduate degree in Finance from The Wharton School at University of Pennsylvania.

Suma Krishnan is the Founder and COO at Krystal Biotech. She has 25 years of drug development experience and has delivered on multiple gene therapy programs from discovery to the clinic as Head of Therapeutics at Intrexon Corporation (NYSE:XON). Previously, she led the discovery, development, and approval of Vyvanse (blockbuster drug to treat ADHD) as SVP, Product Development at New River Pharmaceuticals. Prior to that, Suma advanced approval of Adderall XR and Fosrenol at Shire. She began her career as a discovery scientist for Janssen Pharmaceuticals, Inc. Suma has over 20 publications and 20 issued US patents. She received her Master of Science in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research, and an undergraduate degree in Organic Chemistry from Ferguson University.